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Abstract
Video-assisted thoracoscopic surgery (VATS) is regarded as the standard treat-
ment for lung cancer. However, the feasibility and safety of VATS for lung can-
cer after neoadjuvant chemoradiotherapy (CRT) is unclear. This study evaluated
the feasibility and safety of VATS in patients who had received
neoadjuvant CRT.
Methods: Between January 2008 and December 2017, 85 patients who were
administered neoadjuvant CRT and underwent anatomic lung resection were
enrolled. Fifty-nine patients underwent open thoracotomy and 26 patients under-
went VATS. The clinical characteristics and perioperative outcomes were
reviewed.
Results: In six of the initial 32 patients who underwent VATS, the procedure
was converted to thoracotomy. Adjacent structural invasion (33.9% vs. 11.5%;
P = 0.037) and combined resection (16.9% vs. 0%; P = 0.025) were higher in the
open group than in the VATS group. Surgical duration was higher in the open
group than in the VATS group (203.86  65.97 vs. 173.27  59.87 minutes;
P = 0.046). With regard to postoperative outcomes, the length of the hospital stay
was longer in the open group compared to the VATS group (14.46  16.94
vs. 8.62  4.72 days; P = 0.017). There was no signiﬁcant difference in the three-
year disease-free survival (69.3% vs. 67.9%; P = 0.879) or overall survival rates
(76.6% vs. 61.9%; P = 0.516).
Conclusion: In selected patients, VATS pulmonary resection after neoadjuvant
CRT showed results comparable to that of thoracotomy in terms of postoperative
outcomes, operative morbidities, and survival rate.
Introduction
Since the 1990s, video-assisted thoracoscopic surgery
(VATS) has become a popular method for performing pul-
monary resection for lung cancer and is now regarded as
the standard treatment for early-stage non-small cell lung
cancer (NSCLC).1,2 VATS lobectomy offers more advan-
tages than thoracotomy lobectomy in terms of short-term
postoperative outcomes, including less postoperative pain,
faster postoperative recovery, greater preservation of pul-
monary function, and lower perioperative morbidity.3
Moreover, VATS lobectomy is equivalent to thoracotomy
in terms of oncologic outcomes, including survival and
recurrence rates.4,5
Recent studies have suggested that surgical re-
section following neoadjuvant chemotherapy for patients
with locally advanced NSCLC can signiﬁcantly improve
the complete surgical resection (R0) rate and long-term
survival.2,6,7 However, the feasibility and clinical efﬁcacy of
performing VATS pulmonary resection after neoadjuvant
CRT remains controversial.3,8 The technical difﬁculties
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associated with VATS pulmonary resection following neo-
adjuvant therapy are related to the formation of adhesions
and increased tissue fragility, which affect patient recov-
ery.8 Therefore, the objective of this study was to evaluate
the feasibility and safety of performing anatomical lung re-
section under VATS in patients with advanced-stage lung
cancer who had received neoadjuvant CRT.
Methods
The Institutional Review Board of Severance Hospital
approved this retrospective study (4-2018-0414). Patients
who underwent surgical resection for lung cancer following
neoadjuvant CRT at our institution from January 2008 to
December 2017 were enrolled. Patients who underwent
non-anatomical and sublobar resection were excluded from
this analysis. A total of 85 patients were enrolled in the
study: 59 patients (69.4%) who underwent thoracotomy
(including 6 patients in whom initial VATS was converted
to thoracotomy) were categorized as the Open group; and
26 patients (30.6%) who successfully underwent VATS
were categorized as the VATS group (Fig 1). All enrolled
patients had received cisplatin-based chemotherapy and
radiation therapy prior to surgery.
Surgical methods
Anatomical resection (lobectomy, bilobectomy, or pneu-
monectomy) and mediastinal lymph node dissection were
performed in addition to en bloc removal of any of the
involved adjacent structures, including the large vessels
and chest wall. In the open group, surgical resection under
thoracotomy was performed with an incision placed at the
ﬁfth intercostal space (ICS); an anterolateral incision or
posterolateral incision was also used. In the VATS group,
surgical resection was performed using four incisions. Two
12 mm inferior port incisions were positioned at the level
of the seventh ICS crossing at the anterior axillary line and
the eighth ICS crossing at the posterior axillary line. An
additional posterior 5 mm port incision was positioned
inferior to the scapular tip. A 4 cm incision was created at
the level of the fourth ICS between the latissimus dorsi and
pectoralis major muscles for use as a utility port without
rib spreading. When VATS was converted to open thora-
cotomy, the utility incision was extended to the posterior
5 mm port incision.
Operative outcomes and follow-up
Follow-up and clinical outcome data were collected from
the patients’ medical records. Analytical data included: age;
gender; smoking history; performance status (based on
Eastern Cooperative Oncology Group criteria); pulmonary
function test results; tumor invasion of adjacent structures
(chest wall, mediastinum, and large vessels); and tumor
size, location, and histology. Operative outcomes included
resection type, the need for combined procedures, the pres-
ence of pleural adhesions, surgical duration, and estimated
blood loss. Postoperative outcomes included admission to
the intensive care unit, duration of chest tube drainage,
length of hospital stay, pathologic stage, R0 resection rate,
number of dissected mediastinal lymph nodes (LNs), com-
plications, operative mortality, and recurrence. Complica-
tions included postoperative bleeding, prolonged chest tube
drainage, pneumonia/acute respiratory distress syndrome,
and bronchopleural ﬁstula (BPF). Locoregional recurrence
was deﬁned as intrathoracic disease in the lung or nodal
recurrence in the hilum or mediastinum. Distant metastasis
was deﬁned as extrathoracic metastasis to one or more
organs.
Figure 1 Patient enrollment. VATS,
video-assisted thoracoscopic surgery.
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Statistical analysis
We used descriptive statistics to calculate the percentage,
mean, standard deviation, and median for the selected
demographic and clinical parameters. Comparisons
between the groups were analyzed using Student’s t-test for
continuous variables and the chi-square test for categorical
variables. Survival duration was deﬁned as the period from
the surgery to the time of death. Disease-free survival
(DFS) was deﬁned as the period from the surgery to the
time of recurrence or death. The overall survival (OS) and
DFS rates were compared using the Kaplan–Meier method.
Statistical signiﬁcance was deﬁned as P < 0.05. Statistical
analysis was conducted using SPSS version 23.
Results
Basic characteristics
The baseline characteristics of the patients in each group are
shown in Table 1. The mean age was 60.76  9.90 years in
the open group and 64.31  9.53 years in the VATS group.
The patients were predominately male: 43 patients (72.9%)
in the open group and 18 (69.2%) in the VATS group.
Adjacent structural invasion, including the chest wall and
mediastinal structures, was signiﬁcantly higher in the open
group than in the VATS group (27.1% [16/59] vs. 7.7%
[2/26]; P = 0.043). The number of cases with invasion of
the chest wall was also signiﬁcantly higher in the open
group than in the VATS group (18.6% [11/59] vs. 0%
[0/26]; P = 0.016). Invasion of mediastinal structures,
including large vessels, was reported in 5 (8.5%) patients in
the open group and 2 (7.7%) patients in the VATS group
(P = 1.00). There were no signiﬁcant differences between
the groups with regard to other baseline characteristics.
Additionally, there were no statistically signiﬁcant differ-
ences in terms of primary cancer location, histology, or
clinical stage.
Operative outcomes
Operative outcomes are shown in Table 2. VATS was
converted to thoracotomy in ﬁve patients because of non-
oncologic causes (83.3%) and in one patient because of an
oncologic cause (16.7%). The non-oncologic causes
included four cases of bleeding from the pulmonary artery
(PA) and one case of severe adhesions. The reasons for
thoracotomy conversion are described in Table 2. The case
with an oncologic cause involved a lymph node (LN) that
invaded the pulmonary artery (PA) that required partial
resection of the PA and direct repair to achieve complete
resection. Lobectomy was performed in 50 (84.7%) patients
in the open group and 24 (92.3%) patients in the VATS
group. The number of patients who underwent surgery
combined with other procedures was signiﬁcantly higher in
the open group than in the VATS group (28.8% [17/59]
vs. 7.7% [2/26]; P = 0.031). In the open group, 11 (18.6%)
patients underwent combined chest wall resection,
2 (3.4%) patients underwent resection of the pericardium,
and 4 (6.8%) patients underwent angioplasty. In the VATs
group, one patient underwent partial thymectomy because
of mediastinal soft tissue invasion and one patient under-
went azygos vein resection as a result of direct cancer inva-
sion. One patient in the open group underwent PA
angioplasty as a result of PA tearing without cancer
Table 1 Baseline and preoperative characteristics
Characteristics Open (n = 59) VATS (n = 26) P
Age 60.76  9.90 64.31  9.53 0.125
Gender (male) 43 (72.9%) 18 (69.2%) 0.730
Tuberculosis history 6 (10.2%) 4 (15.4%) 0.492
Smoking 37 (62.7%) 16 (61.5%) 0.918
Pack-year 30.84  18.63 36.13  28.94 0.510
ECOG PS 0.092
0 53 (89.8%) 26 (100%)
1 6 (10.2%) 0
FVC (%) 88.04  15.73 86.36  21.53 0.696
FEV1 (%) 90.87  19.03 91.27  13.54 0.914
Tumor size (cm) 4.24  1.90 3.63  1.56 0.164
Invasion to other
structures
16 (27.1%) 2 (7.7%) 0.043*
Radiation dose (cGy) 4942.80  774.32 4757.50  893.31 0.364
Location 0.050
RUL 14 (23.7%) 11 (42.3%)
RML 1 (1.7%) 2 (7.7%)
RLL 10 (16.9%) 7 (26.9%)
LUL 23 (39.0%) 3 (11.5%)
LLL 8 (13.6%) 2 (7.7%)
> 2 lobes 3 (5.1%) 1 (3.8%)
ECOG PS, Eastern Cooperative Oncology Group performance status;
FEV1, forced expiratory volume after 1 second; FVC, forced vital capacity;
LLL, left lower lobe; LUL, left upper lobe; NSCLC, non-small cell lung can-
cer; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe;
VATS, video-assisted thoracoscopic surgery. *, statistically signiﬁcant.
Table 2 Reasons for conversion to open thoracotomy
Gender Age Reason
Oncologic cause
1 M 58 Metastatic LN on the PA; en bloc resection of LN with
pulmonary artery
Non-oncologic cause
1 M 67 Severe adhesions
2 F 29 Rupture of PA which was previously ligated with clip
3 F 59 Bleeding from segmental PA as a result of calciﬁed
and anthracotic LN
4 M 78 Bleeding from PA as a result of fragile artery tissue
5 M 49 Ruptured PA when encircling
LN, lymph node; PA, pulmonary artery.
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invasion. The surgical duration was signiﬁcantly higher in
the open group than in the VATS group (203.86  65.97
vs. 173.27  59.87 minutes; P = 0.046). There were no sig-
niﬁcant differences with regard to the surgical procedure
or the operative variables between the groups (Table 3).
There was no signiﬁcant difference in the number of dis-
sected LNs between the groups (open 25.32  9.03
vs. VATS 26.45  10.48; P = 0.648). Complete tumor re-
section was not achieved in one patient in the open group
(R1 resection status), but the rate of R0 resection was not
signiﬁcantly different between the groups (open 98.3%
[58/59] vs. VATS 100% [26/26]; P = 0.504). In the patient in
whom complete resection was not achieved, primary cancer
had invaded the PA; although partial resection and repair of
the vessel were performed, the ﬁnal pathologic report
showed cancer invasion in the vascular resection margin.
There were no signiﬁcant differences in the other pathologic
outcomes, including histology and pathologic stage.
Postoperative outcomes
Postoperative outcomes, including the rate of intensive care
unit stay, duration of chest tube drainage, complications,
and postoperative mortality, were not signiﬁcantly different
between the groups (Table 4). The only signiﬁcant differ-
ence was in the length of the hospital stay, which was
14.46  16.94 days in the open group and 8.62  4.72 days
in the VATS group (P = 0.017). The complication rate was
28.8% in the open group and 26.9% in the VATS group
(P = 0.858). The majority of complications were respira-
tory, such as pneumonia and acute respiratory distress syn-
drome (Table 4). Respiratory complications were reported
in nine (15.3%) patients in the open group and four
(15.4%) patients in the VATS group (P = 0.988). The inci-
dence of BPF was higher in the open group, but there was
no signiﬁcant difference between them (open 4 [6.8%]
vs. VATS 1 [3.8%]; P = 0.596). Three patients in the open
group and three in the VATS group died (P = 0.284). All
six of these patients had severe respiratory complications
(pneumonia and acute respiratory distress syndrome) from
which they did not recover.
Prognosis
The median follow-up duration was 12.6 (range: 0–108)
months in all enrolled patients. The recurrence rate was
Table 3 Surgical variables and pathologic ﬁndings
Variables Open (n = 59) VATS (n = 26) P
Procedure 0.251
Lobectomy 50 (84.7%) 24 (92.3%)
Bilobectomy 3 (5.1%) 2 (7.7%)
Pneumonectomy 6 (10.2%) 0
Combined procedure 17 (28.8%) 2 (7.7%) 0.031*
Chest wall resection 11 (18.6%) 0 0.016*
Pericardiectomy 2 (3.4%) 0 1.000
Angioplasty 4 (6.8%) 0 0.308
Other mediastinal resection 0 2 (7.7%) 0.091
Pleural adhesions 30 (50.8%) 14 (53.8%) 0.799
Surgical duration (minutes) 203.86  65.97 173.27  59.87 0.046*
Blood loss (cc) 407.97  788.90 203.19  170.06 0.062
R0 resection 58 (98.3%) 26 (100%) 0.504
Number of LNs dissected 25.32  9.03 26.45  10.48 0.648
Histology 0.417
Squamous cell carcinoma 31 (52.5%) 10 (38.5%)
Adenocarcinoma 25 (42.4%) 15 (57.7%)
Others 3 (5.1%) 1 (3.8%)
ypT stage 0.672
T0~Tis 13 (22.0%) 7 (26.9%)
T1 27 (45.8%) 8 (30.8%)
T2 11 (18.6%) 7 (26.9%)
T3 7 (11.9%) 4 (15.4%)
T4 1 (1.7%) 0
ypN stage 0.285
N0 32 (54.2%) 11 (42.3%)
N1 8 (13.6%) 2 (7.7%)
N2 19 (32.2%) 13 (50.0%)
LN, lymph node; VATS, video-assisted thoracoscopic surgery. *, statistically signiﬁcant.
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12.9% (11/85) in all patients: 15.3% (9/59) in the open
group and 7.7% (2/26) in the VATS group (P = 0.339). In
the open group, three patients (5.1%) had locoregional
recurrence in the lung (n = 1) and mediastinum (n = 2).
Five patients (8.5%) had distant metastases in the liver
(n = 2), brain (n = 2), and bone (n = 1). One patient
(1.7%) had both lung and brain metastases. In the VATS
group, two patients had distant metastases, but no
locoregional recurrence; one patient had metastasis in the
brain, and the other had metastases in the bone and adre-
nal gland. The median recurrence-free interval was 4.4
(range: 2.1–44.0) months in the open group and 4.9 (range:
3.4–6.4) months in the VATS group (P = 0.687) (Table 3).
The three-year DFS (open 69.3% vs. VATS 67.9%;
P = 0.879) and OS rates (open 76.6% vs. VATS 61.9%;
P = 0.516) were not signiﬁcant in either group (Fig 2).
Discussion
VATS anatomic lung resection is considered the standard
treatment for early-stage NSCLC, but in advanced lung
cancer patients who have received neoadjuvant CRT, the
feasibility and safety of pulmonary resection under VATS
is still unclear. The technical difﬁculties associated with
VATS pulmonary resection after neoadjuvant therapy
result from adhesion formation, tissue fragility, and
decreased healing.8 Moreover, radiation therapy leads to
the development of ﬁbrosis, whereby collagen deposition
by ﬁbroblasts into the interstitium leads to chest tissue
edema or adhesions, thus increasing the difﬁculty of
surgery.3,9
In our study, the operative outcomes of the VATS group
were comparable to the open group, suggesting that VATS
pulmonary resection after neoadjuvant CRT is feasible and
safe. In six patients, VATS was converted to thoracotomy,
with a conversion rate of 18.8% (6/32). Only one patient
(3.1%) was converted because of an oncologic cause, which
was the result of a metastatic LN on the PA that was
resected en bloc with the PA. The ﬁve non-oncological
causes (15.6%) were severe adhesions in one patient and
control of bleeding from the PA in the other four. The rea-
sons for each case are as follows: the previous PA ligated
with the clip site had ruptured; bleeding from the segmen-
tal PA as a result of a calciﬁed and anthracotic LN; bleed-
ing from the PA because of fragile PA tissue (in a 78-year-
old man); and a rupture of the PA when it was encircled.
These ﬁndings suggest that neoadjuvant CRT did not
increase the incidence of thoracotomy conversion during
Table 4 Postoperative outcomes
Outcome Open (n = 59)
VATS
(n = 26) P
Admission to the ICU 4 (6.8%) 1 (3.8%) 0.596
Duration of chest tube
drainage (days)
7.81  11.36 6.92  6.47 0.710
Length of hospital stay (days) 14.46  16.94 8.62  4.72 0.017†
Complications 17 (28.8%) 7 (26.9%) 0.858
Bleeding 1 (1.7%) 0 0.504
Prolonged air leakage 4 (6.8%) 2 (7.7%) 0.880
Pneumonia/ARDS 9 (15.3%) 4 (15.4%) 0.988
BPF 4 (6.8%) 1 (3.8%) 0.596
Operative mortality 3 (5.1%) 3 (11.5%) 0.284
Recurrence 9 (15.3%) 2 (7.7%) 0.339
Locoregional 4 (6.8%)† 0 0.174
Distant 6 (10.2%)† 2 (7.7%) 0.719
†One patient in the open group had locoregional and distant recur-
rence. ARDS, acute respiratory distress syndrome; BPF, bronchopleural
ﬁstula; ICU, intensive care unit; VATS, video-assisted thoracoscopic
surgery.
Figure 2 (a) Disease-free survival (DFS) and (b) overall survival (OS). VATS, video-assisted thoracoscopic surgery. ( ), open; ( ), VATS.
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VATS. Our results are similar to those reported in other
studies. The rate of unexpected conversion to thoracotomy
in lung cancer patients without CRT is reported to range
from approximately 2.5% to 23.0%.10 In a previous study,
the reasons for conversion included severe ﬁbrocalciﬁc
LNs and uncontrolled bleeding; only 15.9% of patients
were converted to thoracotomy because of oncological
causes. A different study, in which patients underwent
VATS lobectomy after induction therapy, reported a con-
version rate of 12.5%.2 In the present study, more complex
procedures were performed in the open group than in the
VATS group (28.8% [17/59] vs. 7.7% [2/26]; P = 0.031)
because these patients had more extensive invasion of the
adjacent structures compared to the VATS group (27.1%
[16/59] vs. 7.7% [2/26]; P = 0.043). As a result, the surgi-
cal duration was signiﬁcantly longer in the open group
(P = 0.046).
Induction CRT appeared to increase the risk of postoper-
ative complications by causing changes that led to increased
tissue fragility, delayed tissue healing, and ﬁbrotic changes
in the pulmonary tissues. In previous studies, the incidence
of postoperative respiratory complications in neoadjuvant
chemotherapy (not chemoradiotherapy) patients was
3–4.3%, and the incidence of BPF was 0.7–2%.6,8 In our
study, pneumonia occurred in 15% of patients, and 5.8%
patients developed a BPF. This was slightly higher in the
neoadjuvant CT group in the previous study, but could be
the effect of radiation therapy, which increases tissue fragil-
ity and delays tissue healing. However, our results showed
that there was no difference in the complication rate
according to the surgical approach. The rate of complica-
tions –including BPF, bleeding, and respiratory complica-
tions – was not signiﬁcantly different between the groups
(open 28.8% vs. VATS 26.9%; P = 0.858). The operative
mortality was 7.06% (6/85), which included three patients
from each group; the reason for mortality was respiratory
failure.
With regard to oncologic outcomes, complete re-
section and recurrence rates were comparable between the
groups. In one patient, VATS was converted to thoracot-
omy and complete resection was not achieved. In this
patient, primary cancer had invaded the PA, thus partial
resection and repair of the vessel was performed; the ﬁnal
pathologic report showed cancer invasion in the vascular
resection margin. Eleven patients experienced recurrence,
including two patients from the VATS group. These two
patients had distant recurrences, but no local recurrence,
suggesting that they had undergone sufﬁcient surgical
resection, including mediastinal node dissection. However,
in the open group, there were ﬁve cases of locoregional
recurrence (3 patients had metastases to the lung, 2 had
metastases to the mediastinum). Although these patients
underwent complete resection, these recurrences could be
attributed to the greater frequency of adjacent structure
involvement.
This study has some limitations. First, the study was a
retrospective single-center design. Second, the number of
patients who underwent VATS resection was relatively
small and the follow-up period was short. Finally, the
selection of the surgical procedure performed was based on
the surgeon’s preference. Additional randomized controlled
studies with larger study groups and longer follow-up
periods are needed to overcome the limitations of this
study.
In conclusion, VATS pulmonary resection following
neoadjuvant CRT in selected patients shows results compa-
rable to those of conventional thoracotomy in terms of
postoperative outcomes, operative morbidities, and survival
rate. These ﬁndings suggest that VATS resection could be
safely and effectively performed after neoadjuvant CRT in
selected advanced-stage NSCLC patients who do not
require massive resection of adjacent structures.
Disclosure
No authors report any conﬂict of interest.
References
1 Landreneau RJ, Hazelrigg SR, Ferson PF et al.
Thoracoscopic resection of 85 pulmonary lesions. Ann
Thorac Surg 1992; 54: 415–20.
2 Kamel MK, Nasar A, Stiles BM, Altorki NK, Port JL. Video-
assisted thoracoscopic lobectomy is the preferred approach
following induction chemotherapy. J Laparoendosc Adv Surg
Tech A 2017; 27: 495–500.
3 Huang J, Xu X, Chen H, Shao W, Jiong X, He J. Feasibility
of complete video-assisted thoracoscopic surgery following
neoadjuvant therapy for locally advanced non-small cell
lung cancer. J Thorac Dis 2013; 5 (Suppl 3): S267–73.
4 Tomaszek SC, Cassivi SD, Shen KR et al. Clinical outcomes
of video-assisted thoracoscopic lobectomy. Mayo Clin Proc
2009; 84: 509–13.
5 McKenna RJ Jr, Houck W, Fuller CB. Video-assisted
thoracic surgery lobectomy: Experience with 1,100 cases.
Ann Thorac Surg 2006; 81: 421–5 discussion 425-6.
6 Scagliotti GV, Pastorino U, Vansteenkiste JF et al.
Randomized phase III study of surgery alone or surgery plus
preoperative cisplatin and gemcitabine in stages IB to IIIA
non-small-cell lung cancer. J Clin Oncol 2012; 30: 172–8.
7 Yang CF, Meyerhoff RR, Mayne NR et al. Long-term
survival following open versus thoracoscopic lobectomy after
preoperative chemotherapy for non-small cell lung cancer.
Eur J Cardiothorac Surg 2016; 49: 1615–23.
8 Venuta F, Anile M, Diso D et al. Operative complications
and early mortality after induction therapy for lung cancer.
Eur J Cardiothorac Surg 2007; 31: 714–8.
1246 Thoracic Cancer 10 (2019) 1241–1247 © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd
VATS after induction CRT in lung cancer J.W. Suh et al.
9 Gao SJ, Corso CD, Wang EH et al. Timing of surgery after
neoadjuvant chemoradiation in locally advanced non-small
cell lung cancer. J Thorac Oncol 2017; 12: 314–22.
10 Byun CS, Lee S, Kim DJ et al. Analysis of unexpected
conversion to thoracotomy during thoracoscopic lobectomy
in lung cancer. Ann Thorac Surg 2015; 100: 968–73.
Thoracic Cancer 10 (2019) 1241–1247 © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd 1247
J.W. Suh et al. VATS after induction CRT in lung cancer
